March 21, 2023Frontiers in OncologyOpen Access

Prediction of cardiovascular adverse events in newly diagnosed multiple myeloma: Development and validation of a risk score prognostic model

View Full Paper

Ask AI

Bookmark

Why the study?

The prevalence of cardiovascular adverse events in multiple myeloma has been increasing, and clinical tools for prognostication and risk-stratification are needed.

Population

253 newly diagnosed multiple myeloma patients from two medical centers

Design

Two-center retrospective cohort study

Authors

SYShuai YuanQingdao University JZJie-Yi ZhouNaval Medical Research Command BYBen-Zhao Yang

Discussion

Member takes

Implication

May support CV monitoring in MM; leaves open validation of risk-stratification tools prospectively.

Structured PICO

Population

253 consecutive patients with newly diagnosed multiple myeloma (NDMM) treated in two medical centers, median age 63.0, 59.7% male, based in China. Excluded: Waldenström macroglobulinemia, lymphoma, plasma cell leukemia, systemic light chain amyloidosis (AL amyloidosis), and MM patients who previously had received chemotherapy.

Outcome

Cardiovascular adverse events (CVAEs) assessed by the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0safety

A novel three-factor prognostic model incorporating age >61 years, high baseline office blood pressure, and left ventricular hypertrophy can effectively predict the 1- and 2-year risk of cardiovascular adverse events in patients with newly diagnosed multiple myeloma.

Limitations

Only two independent medical centers were incorporated in our study
Limited number of subjects were included
Traditional factors were not enough to make a difference during follow-up time
Patients who have the history of cardiovascular disease might have received more attention on cardiovascular protection and have less cardiovascular toxicity regimens in the beginning of the therapy

Cite This Study

Yuan et al. (2023) studied this question.

synapsesocial.com/papers/6a76423cd7f18fdd73b1b6d8 https://doi.org/10.3389/fonc.2023.1043869

View Full Paper

Ask AI

Bookmark

Prediction of cardiovascular adverse events in newly diagnosed multiple myeloma: Development and validation of a risk score prognostic model

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Prediction of cardiovascular adverse events in newly diagnosed multiple myeloma: Development and validation of a risk score prognostic model

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider